Author + information
- Zhu Jianbing and
- Junbo Ge
The aim of this study was to examine the outcomes of bare metal stents (BMS) versus c cobalt-chromium everolimus eluting stents (EES) in patients with acute coronary syndrome (ACS).
9 randomized, controlled trials (RCT) involving 2,876 patients were included. We evaluated cardiac mortality and myocardial infarction as primary endpoints. The rates of stent thrombosis, and target vessel revascularisation with ACS were secondary endpoints.
In a comparison of BMS, the rates of cardiac mortality (hazard ratio [HR]:0.48, 95% confidence interval 0.38 to 0.76, p <0.05), stent thrombosis (0.39, 0.25 to 0.86, p <0.05) and myocardial infarction (HR: 0.59, 95% CL: 0.48 to 0.77, p <0.05) of EES for patients with ACS were significantly lower. There was no difference in all cause death (HR: 1.05; 95% CI: 0.80 to 1.58, p > 0.05) between BMS and EES groups.
In patients with ACS, EES comparing with BMS reduced the risk of cardiac mortality, MI and stent thrombosis, improving global cardiovascular outcomes.